Navigation Links
MDS Nordion Divests Non Strategic Product Lines
Date:11/29/2007

Signs contract with Best Medical International Inc.

OTTAWA, Nov. 29 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, today signed an agreement with Best Medical International Inc. to divest its external beam therapy and self-contained irradiator product lines. The sale is a key part of MDS Nordion's growth strategy to focus its resources on being a leading innovator in molecular medicine.

Under the terms of this agreement, Best Medical International Inc., a provider of radiotherapy and oncology products, will purchase MDS Nordion's external beam therapy and self-contained irradiator product lines. External beam therapy equipment is used in the treatment of cancer, and self-contained irradiators are used for the irradiation of blood to prevent disease and for research purposes. Best Medical International Inc. will acquire these two product lines with combined annualized revenues of US $32 million and approximately 150 employees. The transaction is expected to close over the next three months. The financial terms are not being disclosed.

"This sale represents a further focusing of our business at MDS Nordion," said Steve West, President, MDS Nordion. "By divesting these product lines, we can direct all of our energy and resources on becoming a leading innovator in the exciting and growing field of molecular medicine."

The external beam therapy units and blood irradiators are complementary to the kinds of medical equipment manufactured by Best Medical International Inc. With a strategic focus on improving medical care in developing countries, Best Medical International Inc. will provide an opportunity to expand these product lines.

"These product lines are a great fit with our company," said Krishnan Suthanthiran, President, Best Medical International Inc. "The external beam cancer therapy product line complements our portfolio as we will now be able to offer the equipment and services required to set up cancer treatment centres, a move towards our goal of launching war on cancer globally."

About MDS Nordion

MDS Nordion (http://www.mdsnordion.com) is a world leader in medical isotopes, radiation and related technologies. It is a business unit of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global life sciences company that provides market-leading products and services for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS Inc. has more than 6,200 highly skilled people in 28 countries. Find out more at http://www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

About Best Medical International Inc.

For 30 years, Best Medical has served the medical community with the highest quality products and unparalleled customer service. Our brachytherapy seeds, gold fiducial markers, supplies, accessories and exam equipment exemplify our commitment to uncompromised quality and safety. Best Medical International now encompasses a family of trusted companies and organizations with a proven track record of innovation, quality and service in external beam radiation therapy, brachytherapy and vascular brachytherapy solutions. Find out more at http://www.teambest.com.


'/>"/>
SOURCE MDS Nordion
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. MDS Nordion signs 17-year contract with Rosenergoatom
2. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. LehmanMillet Continues Expansion with Strategic Hires
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
7. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
8. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
9. Avantium and BP Extend Strategic Partnership
10. 40 86 Strategic Income Fund Declares Dividend
11. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... staff at Palm Beach Face is proud to announce that their practice founder, Michael ... take place on April 23rd, the London Marathon has a long tradition of raising funds ... team EMPOWER, raising money for the international charity, Smile Train. , Started in ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Chicago plastic ... the removal of osteoma. An osteoma is a benign bony lump located on the ... eye and can cause difficulties with sight and pain. Dr. Shah has discovered an ...
(Date:4/21/2017)... ... , ... Brady (NYSE:BRC), a global leader in industrial and safety ... vinyl label materials received certification for the BS5609 British Marine Standard. This internationally ... legible, for use on chemical drums shipped by sea. , “Achieving BS5609 ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Dudnyk has ... identity emphasizes the agency’s conviction that the full potential of specialty and orphan brands ... equally appreciated and aligned. , “The Unifying Effect is at the heart of ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
Breaking Medicine Technology: